• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

GE blue­prints $165M bi­o­log­ics fa­cil­i­ties; Tarve­da to part­ner with Madri­gal in $163M deal

9 years ago
News Briefing

Sarep­ta rock­ets up af­ter FDA ap­proves its con­tro­ver­sial Duchenne drug

9 years ago
Pharma

Scoop: J&J con­firms that the FDA put AML drug on com­plete hold

9 years ago
R&D

Ben­itec’s aban­doned one-dose hep C “cure” ac­tu­al­ly had two big prob­lems

9 years ago
R&D

Lead vac­cine from Vi­cal and Astel­las flops in a Phase II her­pes study

9 years ago
R&D

Am­gen’s ex­pec­ta­tions for ro­mosozum­ab take a hit as Ra­dius lines up its ri­val os­teo­poro­sis drug

9 years ago
R&D

No­var­tis shows a hole card in a high-stakes PhI­II pok­er game for MS drugs

9 years ago
R&D

Am­gen part­ners with Genen­ta, San Raf­faele on an an­ti-tu­mor drug

9 years ago
News Briefing

Thumbs Up/Thumbs Down: The UN fum­bles bad­ly over ac­cess to drugs while de­vel­op­ers think again about R&D strate­gies

9 years ago
Bioregnum
Opinion

No­vo’s big re­veal: GLP-1 drug semaglu­tide cuts car­dio risks, but just may blind you

9 years ago
R&D

An ac­quis­i­tive Cel­gene looks ready to pop a new mul­ti­ple myelo­ma deal

9 years ago
Deals

Am­gen, No­var­tis cel­e­brate promis­ing mi­graine da­ta, but Te­va and Alder are prepar­ing to crash the par­ty

9 years ago
R&D

The gam­ma delta T cell gam­bit in­spires a small Lon­don biotech start­up with big ideas

9 years ago
Startups

No­vavax shares are rout­ed af­ter its big PhI­II RSV vac­cine tri­al flops

9 years ago
R&D

IPO-bound Intar­cia hauls in $215M, and plans to add more; Pelo­ton rais­es $52M round

9 years ago
News Briefing

Ar­alez fi­nal­ly gets an FDA OK for its car­dio drug Yosprala, starts hir­ing sales reps

9 years ago
Pharma

Mer­ck, Pfiz­er tout PhI­II di­a­betes da­ta as er­tugli­fozin heads to the FDA

9 years ago
R&D

Rigel co-founder, R&D staff jet­ti­soned in the long-await­ed lead up to an FDA pitch

9 years ago
R&D

Ei­sai launch­es biotech di­vi­sion in Mass­a­chu­setts aimed at Alzheimer’s, I/O and au­toim­mune dis­eases

9 years ago
R&D

Acel­Rx takes an­oth­er step in its re­cov­ery pro­gram, prep­ping a pain med pitch to the FDA

9 years ago
R&D

Aerie shares rock­et up as glau­co­ma com­bo drug scores pos­i­tive da­ta

9 years ago
R&D

Agios sets out to raise $150M; AC Im­mune IPO sets val­u­a­tion at $700M

9 years ago
R&D
News Briefing

The FDA con­firms that Sarep­ta neme­sis Ronald Farkas has left the agency

9 years ago
Pharma

Roche’s megablock­buster MS can­di­date ocre­lizum­ab posts promis­ing head-to-head da­ta

9 years ago
R&D
First page Previous page 1164116511661167116811691170 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Confirm Profile

Endpoints News